Favipiravir (T-705) protects against Nipah virus infection in the hamster model /631/326/22/1295 /631/326/596/1296 /13/106 /14/35 /38/77 /82/51 /96/63 article

Scientific Reports

Volumn 8, Issue 1, 2018, Pages

  Dawes, Brian E ^a   Kalveram, Birte ^a   Ikegami, Tetsuro ^a,b   Juelich, Terry ^a   Smith, Jennifer K ^a   Zhang, Lihong ^a   Park, Arnold ^c   Lee, Benhur ^c   Komeno, Takashi ^d   Furuta, Yousuke ^d   Freiberg, Alexander N ^a,b  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d TOYAMA CHEMICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMIDE; FAVIPIRAVIR; PYRAZINE DERIVATIVE;

ANIMAL; DISEASE MODEL; DRUG EFFECT; FEMALE; GENETIC TRANSCRIPTION; HAMSTER; HENDRA VIRUS; HENIPAVIRUS INFECTION; HUMAN; NIPAH VIRUS; ORAL DRUG ADMINISTRATION; PHYSIOLOGY; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME; VIRUS REPLICATION;

ADMINISTRATION, ORAL; AMIDES; ANIMALS; CRICETINAE; DISEASE MODELS, ANIMAL; FEMALE; HENDRA VIRUS; HENIPAVIRUS INFECTIONS; HUMANS; INJECTIONS, SUBCUTANEOUS; NIPAH VIRUS; PYRAZINES; TRANSCRIPTION, GENETIC; TREATMENT OUTCOME; VIRUS REPLICATION;

EID: 85047085438     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-018-25780-3     Document Type: Article

References (55)

1. Selvey, L. A. et al. Infection of humans and horses by a newly described morbillivirus. Med J Aust 162, 642-645 (1995).
2. Chua, K. B. et al. Nipah virus: a recently emergent deadly paramyxovirus. Science 288, 1432-1435 (2000).
3. Ong, K. C. & Wong, K. T. Henipavirus Encephalitis: Recent Developments and Advances. Brain Pathol 25, 605-613 (2015).
4. Rockx, B., Winegar, R. & Freiberg, A. N. Recent progress in henipavirus research: molecular biology, genetic diversity, animal models. Antiviral Res 95, 135-149 (2012).
5. Chua, K. B. et al. Fatal encephalitis due to Nipah virus among pig-farmers in Malaysia. Lancet 354, 1257-1259 (1999).
6. Ching, P. K. et al. Outbreak of henipavirus infection, Philippines, 2014. Emerg Infect Dis 21, 328-331 (2015).
7. Drexler, J. F. et al. Henipavirus RNA in African bats. PLoS One 4, e6367, https://doi.org/10.1371/journal.pone.0006367 (2009).
8. Pernet, O. et al. Evidence for henipavirus spillover into human populations in Africa. Nat Commun 5, 5342, https://doi.org/10.1038/ ncomms6342 (2014).
9. Olson, J. G. et al. Antibodies to Nipah-like virus in bats (Pteropus lylei), Cambodia. Emerg Infect Dis 8, 987-988 (2002).
10. Young, P. L. et al. Serologic evidence for the presence in Pteropus bats of a paramyxovirus related to equine morbillivirus. Emerg Infect Dis 2 (1996).
11. Luby, S. P. The pandemic potential of Nipah virus. Antiviral Res 100, 38-43 (2013).
12. Mire, C. E. et al. A recombinant Hendra virus G glycoprotein subunit vaccine protects nonhuman primates against Hendra virus challenge. J Virol 88, 4624-4631 (2014).
13. Broder, C. C. Passive immunization and active vaccination against Hendra and Nipah viruses. Dev Biol (Basel) 135, 125-138 (2013).
14. Cartwright, D. Hendra virus vaccine trial reveals no ill-effects, http://www.smh.com.au/queensland/hendra-virus-vaccine-trialreveals-no-illeffects-20160627-gpt9nk.html (2016).
15. Geisbert, T. W. et al. Therapeutic treatment of Nipah virus infection in nonhuman primates with a neutralizing human monoclonal antibody. Sci Transl Med 6, 242ra282, https://doi.org/10.1126/scitranslmed.3008929 (2014).
16. Chong, H. T. et al. Treatment of acute Nipah encephalitis with ribavirin. Ann Neurol 49, 810-813 (2001).
17. Pallister, J. et al. Chloroquine administration does not prevent Nipah virus infection and disease in ferrets. J Virol 83, 11979-11982 (2009).
18. Rockx, B. et al. A novel model of lethal Hendra virus infection in African green monkeys and the effectiveness of ribavirin treatment. J Virol 84, 9831-9839 (2010).
19. Freiberg, A. N., Worthy, M. N., Lee, B. & Holbrook, M. R. Combined chloroquine and ribavirin treatment does not prevent death in a hamster model of Nipah and Hendra virus infection. J Gen Virol 91, 765-772 (2010).
20. Georges-Courbot, M. C. et al. Poly(I)-poly(C12U) but not ribavirin prevents death in a hamster model of Nipah virus infection. Antimicrob Agents Chemother 50, 1768-1772 (2006).
21. Lo, M. K. et al. GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses. Sci Rep 7, 43395, https://doi. org/10.1038/srep43395 (2017).
22. Siegel, D. et al. Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses. J Med Chem 60, 1648-1661 (2017).
23. Hotard, A. L., He, B., Nichol, S. T., Spiropoulou, C. F. & Lo, M. K. 4?-Azidocytidine (R1479) inhibits henipaviruses and other paramyxoviruses with high potency. Antiviral Res 144, 147-152 (2017).
24. Furuta, Y. et al. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res 100, 446-454 (2013).
25. Furuta, Y. et al. In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob Agents Chemother 46, 977-981 (2002).
26. Koszalka, P., Tilmanis, D. & Hurt, A. C. Influenza antivirals currently in late-phase clinical trial. Influenza Other Respir Viruses 11, 240-246 (2017).
27. Sangawa, H. et al. Mechanism of action of T-705 ribosyl triphosphate against influenza virus RNA polymerase. Antimicrob Agents Chemother 57, 5202-5208 (2013).
28. Delang, L. et al. Mutations in the chikungunya virus non-structural proteins cause resistance to favipiravir (T-705), a broadspectrum antiviral. J Antimicrob Chemother 69, 2770-2784 (2014).
29. Yamada, K., Noguchi, K., Komeno, T., Furuta, Y. & Nishizono, A. Efficacy of Favipiravir (T-705) in Rabies Postexposure Prophylaxis. J Infect Dis 213, 1253-1261 (2016).
30. Sissoko, D. et al. Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea. PLoS Med 13, e1001967, https://doi.org/10.1371/journal.pmed.1001967 (2016).
31. Jochmans, D. et al. Antiviral Activity of Favipiravir (T-705) against a Broad Range of Paramyxoviruses In Vitro and against Human Metapneumovirus in Hamsters. Antimicrob Agents Chemother 60, 4620-4629 (2016).
32. Yun, T. et al. Efficient reverse genetics reveals genetic determinants of budding and fusogenic differences between Nipah and Hendra viruses and enables real-time monitoring of viral spread in small animal models of henipavirus infection. J Virol 89, 1242-1253 (2015).
33. Safronetz, D. et al. The broad-spectrum antiviral favipiravir protects guinea pigs from lethal Lassa virus infection post-disease onset. Sci Rep 5, 14775, https://doi.org/10.1038/srep14775 (2015).
34. Scharton, D. et al. Favipiravir (T-705) protects against peracute Rift Valley fever virus infection and reduces delayed-onset neurologic disease observed with ribavirin treatment. Antiviral Res 104, 84-92 (2014).
35. Oestereich, L. et al. Evaluation of antiviral efficacy of ribavirin, arbidol, and T-705 (favipiravir) in a mouse model for Crimean-Congo hemorrhagic fever. PLoS Negl Trop Dis 8, e2804, https://doi.org/10.1371/journal.pntd.0002804 (2014).
36. Gowen, B. B. et al. Alterations in favipiravir (T-705) pharmacokinetics and biodistribution in a hamster model of viral hemorrhagic fever. Antiviral Res (2015).
37. Gowen, B. B. et al. Favipiravir (T-705) inhibits Junin virus infection and reduces mortality in a guinea pig model of Argentine hemorrhagic fever. PLoS Negl Trop Dis 7, e2614, https://doi.org/10.1371/journal.pntd.0002614 (2013).
38. Oestereich, L. et al. Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Antiviral Res 105, 17-21 (2014).
39. Tani, H. et al. Efficacy of T-705 (Favipiravir) in the Treatment of Infections with Lethal Severe Fever with Thrombocytopenia Syndrome Virus. mSphere 1, https://doi.org/10.1128/mSphere.00061-15 (2016).
40. DeBuysscher, B. L., Scott, D., Marzi, A., Prescott, J. & Feldmann, H. Single-dose live-attenuated Nipah virus vaccines confer complete protection by eliciting antibodies directed against surface glycoproteins. Vaccine 32, 2637-2644 (2014).
41. Lo, M. K. et al. Single-dose replication-defective VSV-based Nipah virus vaccines provide protection from lethal challenge in Syrian hamsters. Antiviral Res 101, 26-29 (2014).
42. Guillaume, V. et al. Antibody prophylaxis and therapy against Nipah virus infection in hamsters. J Virol 80, 1972-1978 (2006).
43. Rockx, B. et al. Clinical outcome of henipavirus infection in hamsters is determined by the route and dose of infection. J Virol 85, 7658-7671 (2011).
44. Wong, K. T. et al. A golden hamster model for human acute Nipah virus infection. Am J Pathol 163, 2127-2137 (2003).
45. Porotto, M. et al. Inhibition of Nipah virus infection in vivo: targeting an early stage of paramyxovirus fusion activation during viral entry. PLoS Pathog 6, e1001168, https://doi.org/10.1371/journal.ppat.1001168 (2010).
46. Park, A. et al. Optimized P2A for reporter gene insertion into Nipah virus results in efficient ribosomal skipping and wild-type lethality. J Gen Virol 97 (2016).
47. Sidwell, R. W. et al. Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice. Antimicrob Agents Chemother 51, 845-851 [pii] https://doi.org/10.1128/AAC.01051-06 (2007).
48. Bossart, K. N. et al. A neutralizing human monoclonal antibody protects against lethal disease in a new ferret model of acute nipah virus infection. PLoS Pathog 5, e1000642, https://doi.org/10.1371/journal.ppat.1000642 (2009).
49. Bossart, K. N. et al. A neutralizing human monoclonal antibody protects african green monkeys from hendra virus challenge. Sci Transl Med 3, 105ra103, https://doi.org/10.1126/scitranslmed.3002901 (2011).
50. Pessi, A. et al. A general strategy to endow natural fusion-protein-derived peptides with potent antiviral activity. PLoS One 7, e36833, https://doi.org/10.1371/journal.pone.0036833 (2012).
51. Gowen, B. B. et al. Treatment of late stage disease in a model of arenaviral hemorrhagic fever: T-705 efficacy and reduced toxicity suggests an alternative to ribavirin. PLoS One 3, e3725, https://doi.org/10.1371/journal.pone.0003725 (2008).
52. Gowen, B. B. et al. Modeling Severe Fever with Thrombocytopenia Syndrome Virus Infection in Golden Syrian Hamsters: Importance of STAT2 in Preventing Disease and Effective Treatment with Favipiravir. J Virol 91, https://doi.org/10.1128/JVI.01942-16 (2017).
53. Kiso, M. et al. T-705 (favipiravir) activity against lethal H5N1 influenza A viruses. Proc Natl Acad Sci USA 107, 882-887 (2010).
54. O'Sullivan, J. D. et al. Fatal encephalitis due to novel paramyxovirus transmitted from horses. Lancet 349, 93-95 (1997).
55. Tan, C. T. et al. Relapsed and late-onset Nipah encephalitis. Ann Neurol 51, 703-708 (2002).